Department of Medical Protein Research, VIB, B-9000 Ghent, Belgium.
Proteomics Clin Appl. 2013 Jun;7(5-6):388-91. doi: 10.1002/prca.201300020.
Proteomics has fast become a standard tool in the life sciences, with increasingly sophisticated approaches and instruments delivering ever growing numbers of identified and quantified proteins. Yet despite the enormous technological progress, and the triumphant papers published on whole-cell proteomes being collected and analyzed, proteomics has so far failed to enter the clinic for routine applications. This is a peculiar contradiction, and one that warrants some closer study. I here argue that for proteomics to make a difference in the clinic, it needs to stop shirking responsibility, and to mature into an analytical, transparent, and reproducible discipline that also invests in the consolidation of its technology rather than only focusing on the next big leap forward. A key enabling factor in this maturation process is quality control and quality assurance, with bioinformatics, in its least noticeable but most influential form, as a key underlying technology.
蛋白质组学已迅速成为生命科学的标准工具,越来越复杂的方法和仪器提供了越来越多已鉴定和定量的蛋白质。然而,尽管技术取得了巨大进步,并且发表了大量关于收集和分析全细胞蛋白质组的成功论文,但蛋白质组学迄今未能进入临床常规应用。这是一个奇特的矛盾,值得更深入地研究。我认为,为了使蛋白质组学在临床上发挥作用,它需要停止逃避责任,并成熟为一个分析、透明和可重复的学科,不仅要投资于其技术的巩固,还要关注下一个大的飞跃。这一成熟过程的一个关键促成因素是质量控制和质量保证,而生物信息学则以其最不引人注意但最具影响力的形式成为关键的基础技术。